Status:
COMPLETED
Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
To compare the anti-tumour effects as measured by changes in various biomarkers, of a combination of Faslodex and Arimidex with Faslodex alone and Arimidex alone in postmenopausal women patients with ...
Eligibility Criteria
Inclusion
- Postmenopausal women.
- Biopsy confirmation of primary breast cancer.
- Oestrogen receptor positive tumour.
- Fit for surgery within one month.
- Written informed consent to participate in the study
Exclusion
- Previous treatment with any anti-hormonal therapy for breast cancer.
- Previous radiotherapy to the primary tumour.
- Previous chemotherapy for the primary tumour.
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00259090
Start Date
April 1 2004
End Date
October 1 2008
Last Update
August 16 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Nottingham, United Kingdom